Insight Molecular Diagnostics Inc. IMDX 深 滬
等待開盤 03-26 09:30:00 美东时间
4.14
+0.140
+3.50%
華盛通- 最 高4.45
- 今 開4.12
- 成交量 15.93万股
- 最 低 3.69
- 昨 收 4.00
- 總市值 1.33亿
- 52周最高 8.51
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 2.33
- 委 比 35.75%
- 總股本 3214.69万
- 歷史最高 204.80
- 量 比 0.88
- 振 幅 19.00%
- 歷史最低 1.922
- 每 手 1
- 風險率 1.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Insight Molecular Diagnostics Inc. Q4 2025 Earnings Preview
Insight Molecular Diagnostics Inc. (IMDX) is scheduled to announce Q4 earnings results on Thursday, March 26th, after market close. The consensus EPS estimate is -$0.24, and the consensus revenue esti...
今天 05:35
Insight Molecular Diagnostics publishes financial calendar update
Insight Molecular Diagnostics publishes financial calendar update iMDx will report fourth-quarter financial results after the market closes on March 26, 2026. A live Zoom webinar to discuss the results is scheduled for March 26, 2026 at 2:00 pm PT / 5:00 pm ET, with registration at iMDx Q4 2025 Earn
03-20 20:01
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
Insight Molecular Diagnostics Inc. highlighted a new peer-reviewed study demonstrating the potential superiority of its GraftAssure assay technology, featuring 249 biopsy-matched kidney transplant patients. The proprietary Combination Model (CM)-score outperformed percentage-only measures of dd-cfDNA, showing strong correlation with rejection indices, including Antibody-mediated Rejection (AMR) and T-Cell Mediated Rejection (TCMR). The study, con...
03-13 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Edesa Biotech (NASDAQ:EDSA) shares rose 61.0% to $3.67 during Tuesday'...
03-04 01:05
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement
Insight Molecular Diagnostics ( ($IMDX) ) has issued an update. On February 20,...
02-27 05:42
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D
Insight Molecular Diagnostics ( ($IMDX) ) has provided an update. Insight Molec...
02-13 06:51
Insight Molecular Diagnostics Provides Updated Investor Presentation Materials
The latest announcement is out from Insight Molecular Diagnostics ( ($IMDX) ). ...
02-11 21:32
Insight Molecular Diagnostics Commences ~$26M Offering Of 4.526M Common Shares At $5.75/Share
Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), ("iMDx" or the "Company"), today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of an aggregate
02-11 21:01
iMDx Announces $26.0 Million Registered Direct Offering
<p>Insight Molecular Diagnostics Inc. announced the sale of 4.5 million shares at $5.75 each, raising approximately $26 million. The funds will support research and development, particularly expanding GraftAssure to heart transplant testing. The offering is under a shelf registration and Lake Street Capital Markets acted as agent. A significant shareholder, Bio-Rad, also participated. The company aims to use proceeds for general corporate purpose...
02-11 13:00
